Sierra Oncology, Inc…today announced the signing of a clinical supply agreement with Janssen Research & Development, LLC. (Janssen) for access to TESARO's ZEJULA (niraparib)… Sierra intends to evaluate its Chk1 inhibitor, SRA737, in combination with niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC).
In other words, JNJ is furnishing TSRO’s Zejula to SRRA at a (greatly) reduced price. JNJ, who is conducting its own combination trials with Zejula, presumably has an interest in seeing the results of SRRA’s trial. SRRA is nevertheless down 7% today.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.